However, even in the responsive patients, olaparib only moderately extended life, from 4.2 months to 7 months on average, in comparison with the standard therapy group (42), which highlights the need for effective therapeutic treatment strategies for BRCA1 mutation–associated breast cancer (43). This evidence concerns the gene BRCA1 and breast carcinoma.